Physician profile
Mitchell Machado
NPI 1265520100
$6,866.17
in general payments reported to CMS, 2019-2025
15 companies · $80.00 in 2025
The $80.00 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,640 · 2020: $24.09 · 2021: $948 · 2022: $2,189 · 2023: $478 · 2024: $507 · 2025: $80.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.76 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,858.41 | 2019-2024 | Imfinzi, Tagrisso |
| Karyopharm Therapeutics INC. | $1,954.55 | 2022-2024 | Xpovio |
| Adaptive Biotechnologies Corporation | $880.33 | 2021-2022 | |
| Genzyme Corporation | $245.89 | 2023 | |
| Celgene Corporation | $133.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.40 | 2019 | |
| Intuitive Surgical, INC. | $129.34 | 2024 | |
| Kite Pharma, INC. | $116.27 | 2023 | Yescarta |
| Stemline Therapeutics INC. | $112.00 | 2024 | Orserdu |
| Merck Sharp & Dohme LLC | $110.22 | 2019 | |
| Janssen Biotech, INC. | $110.15 | 2022-2025 | Erleada |
| Alnylam Pharmaceuticals INC. | $28.45 | 2024 | Onpattro |
| Daiichi Sankyo INC. | $24.09 | 2020 | |
| Agios Pharmaceuticals, INC. | $15.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Machado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.